Background: Brusini’s recently introduced glaucoma staging system (GSS) categorizes visual-field damages into different types (i.e. generalized, mixed and localized) and classifies them into stages similar to those of Aulhorn-Karmeyer. Basically, the Brusini GSS is a scatterplot of mean defect (x-axis) and corrected loss variance (CLV; y-axis). The Brusini GSS charts are claimed to be simple to understand due to their 2-dimensional spatial representation and there is no subjective interpretation necessary, since their numerical presentation provides an objective evaluation. Inter- and intraindividual comparisons are, thus, provided ‘at a glance’. Methods: Retrospectively, 610 visual fields (Octopus 201, Program G1) for each eye of 32 glaucoma patients were inspected on screen with PeriData 7.0. The performance of the Brusini GSS was evaluated in terms of typing of visual-field defect and staging as defined by the Aulhorn-Karmeyer classification. Results: Typing of defects into ‘normal’ and various degrees of generalized and localized damage agreed with PeriData in 89% of fields; 5% were wrongly classified as normal by the Brusini GSS. The type of visual defect showed in 1.3% fields as marked and in 5% a minor discrepancy. Most of the 11% of nonagreement was due to high short-term fluctuation. Agreement could potentially be enhanced by using loss variance instead of CLV. Staging of visual-field defects with Brusini GSS charts was in agreement with the Aulhorn-Karmeyer classification in 73% of fields. Conclusion: The authors recommend the Brusini GSS because of its simplicity to concisely describe visual-field damage for clinical use as well as research work and because of the remarkably good agreement with the well-known Aulhorn-Karmeyer classification.

Keywords:
Visual field, Automated perimetry, Glaucoma, Brusini glaucoma staging system, Aulhorn-Karmeyer staging
This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.